GB0228490D0 - Novel imaging compounds - Google Patents

Novel imaging compounds

Info

Publication number
GB0228490D0
GB0228490D0 GBGB0228490.9A GB0228490A GB0228490D0 GB 0228490 D0 GB0228490 D0 GB 0228490D0 GB 0228490 A GB0228490 A GB 0228490A GB 0228490 D0 GB0228490 D0 GB 0228490D0
Authority
GB
United Kingdom
Prior art keywords
novel imaging
imaging compounds
compounds
novel
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0228490.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
Amersham PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham PLC filed Critical Amersham PLC
Priority to GBGB0228490.9A priority Critical patent/GB0228490D0/en
Publication of GB0228490D0 publication Critical patent/GB0228490D0/en
Priority to CNA2003801095526A priority patent/CN1744890A/zh
Priority to CA002508663A priority patent/CA2508663A1/en
Priority to EP03767961A priority patent/EP1567141A1/en
Priority to AU2003292384A priority patent/AU2003292384B2/en
Priority to US10/537,103 priority patent/US20060239915A1/en
Priority to RU2005116983/15A priority patent/RU2005116983A/ru
Priority to JP2004558793A priority patent/JP2006514945A/ja
Priority to PCT/GB2003/005319 priority patent/WO2004052357A1/en
Priority to NO20052633A priority patent/NO20052633L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0228490.9A 2002-12-06 2002-12-06 Novel imaging compounds Ceased GB0228490D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0228490.9A GB0228490D0 (en) 2002-12-06 2002-12-06 Novel imaging compounds
PCT/GB2003/005319 WO2004052357A1 (en) 2002-12-06 2003-12-05 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases
AU2003292384A AU2003292384B2 (en) 2002-12-06 2003-12-05 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases
CA002508663A CA2508663A1 (en) 2002-12-06 2003-12-05 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases
EP03767961A EP1567141A1 (en) 2002-12-06 2003-12-05 Labeled macrophage scavenger receptor antagonists for imaging cardiovacular diseases
CNA2003801095526A CN1744890A (zh) 2002-12-06 2003-12-05 用于心血管疾病成像的标记的巨噬细胞清除剂受体拮抗剂
US10/537,103 US20060239915A1 (en) 2002-12-06 2003-12-05 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases
RU2005116983/15A RU2005116983A (ru) 2002-12-06 2003-12-05 Меченые антагонисты фагоцитарных рецепторов макрофагов для визуализации сердечно-сосудистых заболеваний
JP2004558793A JP2006514945A (ja) 2002-12-06 2003-12-05 循環器疾患造影用の標識マクロファージスカベンジャー受容体拮抗薬
NO20052633A NO20052633L (no) 2002-12-06 2005-06-01 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0228490.9A GB0228490D0 (en) 2002-12-06 2002-12-06 Novel imaging compounds

Publications (1)

Publication Number Publication Date
GB0228490D0 true GB0228490D0 (en) 2003-01-08

Family

ID=9949200

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0228490.9A Ceased GB0228490D0 (en) 2002-12-06 2002-12-06 Novel imaging compounds

Country Status (10)

Country Link
US (1) US20060239915A1 (https=)
EP (1) EP1567141A1 (https=)
JP (1) JP2006514945A (https=)
CN (1) CN1744890A (https=)
AU (1) AU2003292384B2 (https=)
CA (1) CA2508663A1 (https=)
GB (1) GB0228490D0 (https=)
NO (1) NO20052633L (https=)
RU (1) RU2005116983A (https=)
WO (1) WO2004052357A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7886497B2 (en) 2003-12-02 2011-02-15 Valinge Innovation Ab Floorboard, system and method for forming a flooring, and a flooring formed thereof
GB0428020D0 (en) 2004-12-22 2005-01-26 Amersham Health As Stabilisation of radiopharmaceutical precursors
WO2006077901A1 (ja) * 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf発現阻害剤
MX2010005122A (es) * 2007-11-07 2010-08-18 Ge Healthcare Bv Estabilizacion de radiofarmaceuticos.
US11725395B2 (en) 2009-09-04 2023-08-15 Välinge Innovation AB Resilient floor
ES2985671T3 (es) 2009-09-04 2024-11-06 Vaelinge Innovation Ab Suelo elástico
JP6105587B2 (ja) 2011-08-29 2017-04-05 セラロック、イノベーション、アクチボラグ フロアパネル用機械式係止システム
EP3656944A1 (en) 2013-03-25 2020-05-27 Välinge Innovation AB Floorboards provided with a mechanical locking system and a method to produce such a locking system
EP4140991B1 (en) * 2018-06-01 2024-05-15 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
WO2000078145A1 (en) * 1999-06-24 2000-12-28 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
WO2001098264A1 (en) * 2000-06-21 2001-12-27 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
AU2002254000A1 (en) * 2001-02-23 2002-09-12 Bristol-Myers Squibb Pharma Company Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque

Also Published As

Publication number Publication date
CN1744890A (zh) 2006-03-08
NO20052633D0 (no) 2005-06-01
JP2006514945A (ja) 2006-05-18
WO2004052357A1 (en) 2004-06-24
US20060239915A1 (en) 2006-10-26
RU2005116983A (ru) 2006-02-27
AU2003292384A1 (en) 2004-06-30
CA2508663A1 (en) 2004-06-24
EP1567141A1 (en) 2005-08-31
AU2003292384B2 (en) 2007-04-19
NO20052633L (no) 2005-07-06

Similar Documents

Publication Publication Date Title
GB0202216D0 (en) Novel compounds
GB0205256D0 (en) Novel compounds
GB0202679D0 (en) Novel compounds
GB0206723D0 (en) Novel compounds
GB0207249D0 (en) Novel compounds
GB0228490D0 (en) Novel imaging compounds
GB0207246D0 (en) Novel compounds
GB0203299D0 (en) Novel compounds
GB0200025D0 (en) Novel compounds
GB0204252D0 (en) Novel compounds
GB0203437D0 (en) Novel compounds
GB0200787D0 (en) Novel compounds
GB0202217D0 (en) Novel compounds
GB0202219D0 (en) Novel compounds
GB0202442D0 (en) Novel compounds
GB0202636D0 (en) Novel compounds
GB0202637D0 (en) Novel compounds
GB0202140D0 (en) Novel compounds
GB0201357D0 (en) Novel compounds
GB0203300D0 (en) Novel compounds
GB0203301D0 (en) Novel compounds
GB0203363D0 (en) Novel compounds
GB0203369D0 (en) Novel compounds
GB0201231D0 (en) Novel compounds
GB0201211D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)